{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:14:51Z","timestamp":1767914091240,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.ymgme.2006.11.008","type":"journal-article","created":{"date-parts":[[2006,12,23]],"date-time":"2006-12-23T12:14:17Z","timestamp":1166876057000},"page":"307-312","source":"Crossref","is-referenced-by-count":35,"title":["Cellular and tissue distribution of intravenously administered agalsidase alfa"],"prefix":"10.1016","volume":"90","author":[{"given":"Gary J.","family":"Murray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam R.","family":"Anver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen A.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane M.","family":"Quirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2006.11.008_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.11.008_bib2","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1001\/jama.284.21.2771","article-title":"Clinical features of and recent advances in therapy for Fabry disease","volume":"284","author":"Brady","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2006.11.008_bib3","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2006.11.008_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymgme.2006.11.008_bib5","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trail","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2006.11.008_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.11.008_bib7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2006.11.008_bib8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2006.11.008_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2006.11.008_bib10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2006.11.008_bib11","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(05)67636-2","article-title":"Fabry\u2019s disease\u2013an important risk factor for stroke","volume":"366","author":"Schiffmann","year":"2005","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2006.11.008_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1023\/A:1012451320105","article-title":"Enzyme replacement therapy in Fabry disease","volume":"24","author":"Brady","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2006.11.008_bib13","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1073\/pnas.120177997","article-title":"Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells","volume":"97","author":"Takenaka","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2006.11.008_bib14","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2006.11.008_bib15","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"Ohshima","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2006.11.008_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2006.11.008_bib17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0021-9258(17)38286-8","article-title":"Purification and properties of the two major isozymes of \u03b1-Galactosidase A from human placenta","volume":"253","author":"Kusiak","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2006.11.008_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","article-title":"Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry\u2019s disease","volume":"112","author":"Mayes","year":"1981","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2006.11.008_bib19","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1212\/01.wnl.0000247278.88077.09","article-title":"Myeloperoxidase predicts risk for vasculopathic events in hemizygous males with Fabry disease","volume":"67","author":"Kaneski","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2006.11.008_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2006.11.008_bib21","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1210\/endo-122-6-2753","article-title":"Distribution of insulin-like growth factor II receptor immunoreactivity in rat tissues","volume":"122","author":"Valentino","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.ymgme.2006.11.008_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1677\/joe.0.1150035","article-title":"Comparison of receptors for insulin-like growth factor II from various rat tissues","volume":"115","author":"Taylor","year":"1987","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ymgme.2006.11.008_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/eje.0.1300265","article-title":"Identification and characterization of insulin-like growth factor I (IGF-I) and IGF-II\/mannose-6-phosphate (IGF-II\/M6P) receptors in bovine adrenal cells","volume":"130","author":"Weber","year":"1994","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ymgme.2006.11.008_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1083\/jcb.100.2.418","article-title":"Endothelial fenestral diaphragms: a quick-freeze, deep-etch study","volume":"100","author":"Bearer","year":"1985","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.ymgme.2006.11.008_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ar.1092080404","article-title":"Ultrastructure of the secretory epithelium, nerve fibers, and capillaries in the mouse sweat gland","volume":"208","author":"Quick","year":"1984","journal-title":"Anat. Rec."},{"key":"10.1016\/j.ymgme.2006.11.008_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-005-0089-x","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement","volume":"448","author":"Schiffmann","year":"2006","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ymgme.2006.11.008_bib27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2006.11.008_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bbrc.2005.05.207","article-title":"Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain","volume":"337","author":"Lee","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2006.11.008_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejps.2005.10.011","article-title":"The kinetics and tissue distribution of protein transduction in mice","volume":"27","author":"Cai","year":"2006","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719206003611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719206003611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T02:35:56Z","timestamp":1628303756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719206003611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1096719206003611"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2006.11.008","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}